Lyell Immunopharma Inc   (LYEL)
Other Ticker:  
Price: $1.6700 $0.03 1.829%
Day's High: $1.825 Week Perf: -3.47 %
Day's Low: $ 1.64 30 Day Perf: -6.7 %
Volume (M): 866 52 Wk High: $ 4.27
Volume (M$): $ 1,446 52 Wk Avg: $2.52
Open: $1.64 52 Wk Low: $1.32

 Market Capitalization (Millions $) 420
 Shares Outstanding (Millions) 251
 Employees -
 Revenues (TTM) (Millions $) 49
 Net Income (TTM) (Millions $) -190
 Cash Flow (TTM) (Millions $) 170
 Capital Exp. (TTM) (Millions $) 7

Lyell Immunopharma Inc
Lyell Immunopharma Inc is a biotechnology company focused on the development of next-generation cell therapies for cancer treatment. The company is headquartered in South San Francisco, California, and is led by CEO and co-founder, Rick Klausner. The company was founded in 2018, and has raised over $493 million in funding to date.

Lyell Immunopharma's mission is to transform cancer treatment by developing new cell therapies that enhance the body's natural immune system to fight cancer. The company is focused on developing personalized cell therapies that target specific types of cancer, improving the effectiveness of current treatments and reducing the side effects associated with traditional treatments.

Lyell Immunopharma is developing a platform that combines the latest advances in synthetic biology with sophisticated gene editing technologies to create powerful immune cells that can specifically target cancer cells. The company's proprietary technology is based on a novel approach called Synthetic Control of Cellular Circuits (SynC3), which enables the design of precise and customizable cell therapies that can respond to changing conditions within the body.

Lyell Immunopharma's lead product candidate is LY-501, a personalized cell therapy that targets solid tumors. The company is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of LY-501 in patients with advanced solid tumors. The company also has several other programs in preclinical development, including CAR-T and TCR therapies for different types of cancer.

Lyell Immunopharma has received significant funding from several high-profile investors, including ARCH Venture Partners, Foresite Capital, and the Alaska Permanent Fund. The company also has partnerships with several leading academic institutions, including the University of California, San Francisco, and the Massachusetts Institute of Technology.

In summary, Lyell Immunopharma is a biotechnology company that is focused on developing next-generation cell therapies for cancer treatment. The company's mission is to transform cancer treatment by developing personalized cell therapies that enhance the body's natural immune system to fight cancer. With its proprietary SynC3 platform, the company is developing powerful and customizable cell therapies that can respond to changing conditions within the body. The company's lead product candidate, LY-501, is currently in clinical trials and the company has several other programs in preclinical development.

   Company Address: 201 Haskins Way South San Francisco 94080 CA
   Company Phone Number: 695-0677   Stock Exchange / Ticker: NASDAQ LYEL
   LYEL is expected to report next financial results on February 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Lipocine Inc

the Major Pharmaceutical Preparations company in the fiscal time-frame ending September 30 2023

In its most recent fiscal period Lipocine Inc increased a shortfall per share at $-1.27 per share, opposite of $-0.03 per share a year before reporting season, In the prior reporting season LPCN realized $-0.68 per share.

Bioxytran Inc

Bioxytran Inc Faces Investor Concerns as Operating Deficit Grows in Q3 2023

Following the recent announcement of operating deficit for the third quarter of 2023, Bioxytran Inc, a major player in the pharmaceutical preparations industry, has captured investors' attention. The company's financial performance has raised questions about its ability to generate revenue in the near future.
For the third quarter of 2023, Bioxytran Inc reported an operating deficit of $-0.985464 million. This represents a worsening of the deficit compared to the same period in 2022, where it stood at $0.014225 million. However, the main concern for investors lies in the absence of any reported revenue during this time frame.

Briacell Therapeutics Corp

Briacell Therapeutics Corp Releases Fourth Quarter Fiscal Results - Showcasing Impressive Growth in Major Pharmaceutical Preparations Sector

The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.

Gt Biopharma Inc

GTBP Reports Impressive Operating Surplus of $3.122 Million in Third Quarter Earnings Season

The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.


Lyell Immunopharma Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com